Background High-end medical devices—such as software/artificial intelligence (AI)-based medical devices—continue to advance rapidly, and are now widely used in healthcare systems around the globe. However, the current regulatory system in China is still based on high-risk, hardware-based medical devices, which causes problems for manufacturers of software and AI-based high-end medical Read more…
Background A sudden wave of Omicron outbreaks in March 2022 seriously affected cosmetics companies’ progress in adapting to new regulations on registration and notification, making it impossible for companies to complete the necessary paperwork by the 1st May 2022 official deadline. Result Considering the huge impact of the COVID-related lockdowns Read more…
Background The development of originator drugs on average takes up to 12 years and costs more than EUR 2 billion. However, new drugs are easily copied, and the lengthy patent registration and drug regulatory processes take up the originator drug’s patent term and reduce its lifespan in the market. In Read more…
Background Since the beginning of 2020, demand for green energy among European manufacturing companies based in Tianjin has become increasingly urgent, due to concrete global targets set by their headquarters aimed at reducing carbon emissions within the next five to 10 years. However, there is currently a shortage of renewable Read more…
Background Since March 2020, Europe has been struggling to contain COVID-19, with some countries seeing multiple waves of outbreaks, causing the demand for medical supplies to soar. On 31st March 2020, the Ministry of Commerce (MOFCOM), the General Administration of Customs (GAC) and the National Medical Products Administration jointly issued Read more…
Background On 2nd December 2019, the State Administration for Market Regulation (SAMR) issued the Interim Measures for Handling Complaints and Reports Concerning Market Supervision and Administration, which states that market supervision and administration agencies should not accept complaints arising from circumstances such as “purchases not made for lifestyle and consumption Read more…
Background On 4th March 2021, the National Medical Products Administration (NMPA) officially released the Provisions for Management of Cosmetic Registration and Notification Dossiers (Provisions), which take effect from 1st May 2021. These Provisions finally conditionally waive the requirement for animal testing of non-special cosmetics imported into China, which has been in place Read more…
Equally qualified to participate in the competition of procurement of medical equipment.
Less restrictive talent policy helped member companies with their issues in hiring foreign employees.
The CMDE can conduct remote review through the video platform of the European Chamber.
